Share Name Share Symbol Market Type Share ISIN Share Description
Shield Therapeutics Plc LSE:STX London Ordinary Share GB00BYV81293 ORD 1.5P
  Price Change % Change Share Price Shares Traded Last Trade
  35.50 38.8% 127.00 713,124 16:29:35
Bid Price Offer Price High Price Low Price Open Price
125.00 129.00 130.50 91.50 91.50
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.72 -9.07 -8.00 149
Last Trade Time Trade Type Trade Size Trade Price Currency
17:08:29 O 12,501 127.00 GBX

Shield Therapeutics (STX) Latest News (2)

More Shield Therapeutics News
Shield Therapeutics Takeover Rumours

Shield Therapeutics (STX) Discussions and Chat

Shield Therapeutics Forums and Chat

Date Time Title Posts
06/8/202023:35Shield Therapeutics: poised for a US licensing deal3
06/8/202022:20Shield Therapeutics 3,746
06/8/202021:59Shield Therapeutics: Poised for a US deal-
22/2/202021:14Seagate Technology2,674

Add a New Thread

Shield Therapeutics (STX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2020-08-06 16:08:29127.0012,50115,876.27O
2020-08-06 15:40:17125.0051,00063,750.00O
2020-08-06 15:29:53125.00392490.00O
2020-08-06 15:29:30127.00411521.97O
2020-08-06 15:28:21127.00416528.32O
View all Shield Therapeutics trades in real-time

Shield Therapeutics (STX) Top Chat Posts

Shield Therapeutics Daily Update: Shield Therapeutics Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker STX. The last closing price for Shield Therapeutics was 91.50p.
Shield Therapeutics Plc has a 4 week average price of 82p and a 12 week average price of 82p.
The 1 year high share price is 195p while the 1 year low share price is currently 40p.
There are currently 117,188,657 shares in issue and the average daily traded volume is 55,431 shares. The market capitalisation of Shield Therapeutics Plc is £148,829,594.39.
shandypants2: to reinforce Peachies point did you see REDX yesterday. Went up c300% at one point and is now valued at over £100m based on a deal it signed with Astra Zeneca. $17m upfront and upto £360m in milestones payments. Now i am definitely not saying US deal will have the same impact on STX, it is a larger company for a start, but deal , if similar to Europe and China, will have an upfront payment, additional milestone payments plus royalties. FinnCap has estimate upfront could be as high as $50m and milestones c$100m. Even if we only get say 80% of quoted figures as none of this appears to be factored into share price, or current broker estimates, this will have a transformational impact on the share price. IMHO i will be surprised if we don't have a minimum 50% increase when RNS drops. It is frustrating to see MMs drop the share price almost daily on small volunes but we know this can move quickly. Keep the faith!!!
shandypants2: always a few positive and negative views re US deal. I'm with Nobby, i was hoping for end of July, but if it needs to go into August i'm not too bothered. In additional to Peel and Hardman research notes and valuations of c£2, FinnCap has a £3.5 valuation based on quite conservative NPVs from US and Europe and China is excluded, as not yet achieved regulatory approval. From the FinnCap research... Shield confirmed that it has had considerable interest in Accrufer from a number of US-based companies, ranging from relatively small ones (which focus on single therapeutic areas) to larger organisations (which span several of the therapeutic areas in which Accrufer is relevant). Management is seeking a partner with the optimal combination of capability and favourable financial terms. We still believe that the NPV of any deal will be considerably higher than the current share price indicates, driven by a significant upfront payment, commercial-based milestones and royalties on sales.
shandypants2: thanks for the update Peachie, pretty much as i expected really, what else can they say. Re US progress i do think they missed a trick at the AGM. With covid restrictions i think it was an ideal time to issue a statement. Even comments such as 'progressing to plan' and/or 'short list of potential partners has been completed' would not have been price sensitive but hopefully would have reassured the market. Clearly if discussions are at an advance stage no news is actually good news. Although STX won't openly criticise ex CEO the fact they have stated US deal with be with a single company suggests to me that Carl Sheritt wanted to do a number of different US deals to maximise value and larger US pharmas were less keen on this arrangement. Chinese deal was announced without any rumours and price drop before successful FDA announcement suggests that STX is not a leaky company so i can see US deal just dropping without any fanfare. I am also in the 5 figure loss camp but am pretty confident we will see a 50% one day rise when deal is announced (as long as half decent) and hopefully £1.50 plus share price in the next month or so
shandypants2: IMHO there was definitely an US deal lined up in late 2019 but for some reason this didn't materialise. Personally, i suspect ex CEO as founder wanted the perfect deal and wouldn't compromise. Him moving on is clearly a sign that a couple of large shareholders have voiced their displeasure. Current timeline is summer of 2020 (slipped from Q2) so July or August. I suspect they are close and feel a July deal is still doable, with August included as a bit of contingency. As with all deals the upfront and royalty amounts will be the stumbling block with both sides wanting the best deal possible. Both sides will probably need to compromise, although if there are more than one bidder that will strengthen STX's hand. If it doesn't happen on Sept 1st it's not a disaster but i feel the market will not be impressed. In terms of a takeover last year with the share at £1.80 it probably needed a £4 bid to interest STX (valuing company at c£500m). Today it is valued at just over £100m so even a £200m bid would need to be seriously considered. As one shareholder has over 45% of the company's shares get them on board and the rest will follow. Personally i'm not expecting a takeover but reckon an US deal will be in place late July/early August. Share price will not get back to £2 in the short term but will be over £1.50 once this lands
shandypants2: at current share price even a very conservative £1.50 share price after an US deal would result in a c65% uplift - the risk v reward is very compelling at the moment. If it's over £2 as has previously been estimated you have an immediate bagger. AGM is on 18th June so it will be interesting to see the statement re US deal. Clearly if negotiations are ongoing no price sensitive info can be disclosed but the tone of the comment will be on interest. I am hoping that CEO uses words such as positive and constructive etc. I am also hoping he confirms current timeline which is summer 2020 and not H2 2020. At recent presentation in answer to the question re the possibility of an US deal - CEO stated 'High'. That's good enough for me.
borromini1: EKCS - thanks for your reply, I may be wrong. The interest in the H2H analysis is in the 0 to 12 weeks period and how that competes with the proven beneficial immediacy of Ferinject, the STX simplistic presentation bar chart shows a distinct difference in performance in the first period with Feraccru catching up later. In early February I discussed this with Tim and his response was that the detailed analysis paper to be published soon will provide much better insight into the early better than depicted performance shown by the presentation bar chart. The impression given was that the detailed analysis would have a positive impact on the equivalence performance in relation to Ferinject in the first twelve weeks. This and the article as a whole would further support the value and pricing strategy for Feraccru in all subsequent pricing negotiations, whether used by Norgine or in conjunction with the US deal. That is why the error and delay is a shame and has a broad range of consequences not fully recognised on this BB. Will it stop the US deal by the end of summer or by the end of 2020, probably not, will this and other delays drop the share price from 180 GBX to 100 GBX, yes.
ekcs: So it is fair to say that the market opportunity is clear for all to see. Yes, like any company STX has had a few hiccups (and unfairly these have happened during the current global crisis meaning there has been excessive punishment to the share price), but seemingly new people are there to drive it forward (the new Chair 's CV suggests he's both an experienced financier and deal-maker, which surely should bode well. I guess the best thing to do is ask the CEO at the event this evening if questions are allowed. Reading the AR (probably because of the auditor and NOMAD combined and the fact the CEO has lots of experience as a CFO), they seem to be really over-doing the going concern concerns, bearing in mind they can surely delay the multi-million pound kids study (which probably gets delayed anyway due to coronavirus when you look at all the other studies that have suffered delays recently if not looking at something to do with COVID-19). Presumably they also would not start that study until a US deal was done - why take the risk? Another reason why the cash runway should go well beyond Q1. It would be nice for them to say that. It would have been nice of them to explain these levers rather than just make bland statements that raise concerns. Of course even a poor deal should completely remove any long-term funding issues. On that point it would be good to have an understanding of the current status of negotiations (do they have basic terms agreed etc...) and also the anticipated range of terms, i.e. are the guidances given by finnCap et al reasonable assumptions or grossly over-estimating what will be delivered? Perhaps if potential investors had that level of colour they may well dip their toes in the the share price might respond positively etc...
peachie 74: More evidence of its efficacy as an IV alternative. US market itself is massive, “just looking at that table again - CEO has previously stated target of 10% of US market is quite conservative. Based on chart 10% will generate £2.4bn for STX which is an NPV of £1.6bn. STX has 117m shares in issue so that's over £10 a share (if share price valued at NPV). Even at 50% of NPV that's over £5 a share and excludes Europe and China etc Upside here is massive!!!” Post from LSE. Bullish , but based on factual numbers
kop202: Its typical AIM. The share price is "made up" by the intermediaryIn the development phase they inflate the share price based on what the company could be potentially. Punters get carried away......Then before the potential is likely to be realised they drop the share price and base it on fundamentals......and leave there...AIM is run by City Scum.
stevee1234: Hi Nobby, yes agree more buys recently, maybe we're about as low as it gets before more buyers stop the drop. I'm just trying to explain why I believe the share price has moved as it has over the last three weeks. It's a question of "do sellers prompt the share price to drop" or "do price drops prompt holders to sell" obviously a bit of both but on AIM I think the MMs know that when a share has had a good run recently dropping the price can often stimulate profit taking and hence allow them to get some shares back ready for the next upward step. I believe people are more motivated to buy when the chare price rises and sell when the share price falls, hence when stx stalled at 120ish they have been progressively stimulating the market by dropping the price, hopefully in coming weeks they'll be stimulating the market by raising the price. Still as I said everything crossed for the main event hopefully soon.
Shield Therapeutics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Shield The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200807 05:08:06